mHSPC VL

A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore

Details
Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT. Drs. Shore and Morgans speak about the clinical implications of this approval from a urologist's perspective. The approval was based on the overall survival data Matthew Smith presented at ASCO GU 2022 and the 32% reduction in mortal...

Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal

Details
In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...

Darolutamide Approved for Patients with mHSPC - Charles Ryan

Details
Drs Charles Ryan and Alicia Morgans discuss the approval of NUBEQA® (darolutamide) tablets, for oral use for metastatic hormone-sensitive prostate cancer (mHSPC). The FDA has approved darolutamide in combination with docetaxel for adult patients with mHSPC. This regulatory decision is based on findings from the phase 3 ARASENS trial. ARASENS is a randomized phase 3 trial of darolutamide versus pla...

De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal

Details
In this conversation with Alicia Morgans, Bertrand Tombal discusses de-escalation treatment strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC). They discuss treatment optimization, and how we candefine the minimal dose or duration of a treatment to achieve similar efficacy while preserving quality of life, decreasing side effects, and decreasing resource utilizati...

When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi

Details
In a discussion on the management of metastatic hormone-sensitive prostate cancer (mHSPC) Karim Fizazi joins Alicia Morgans in discussing when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of Paris-Saclay in Villej...

The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore

Details
Neal Shore joins Alicia Morgans to discuss pioneering work on establishing the importance of multidisciplinary teams in the management of urologic oncology patients. This was a plenary presentation at the AUA led by Leonard Gomella and Neal Shore and Michael Cookson as panelists. They discussed the importance of a collaborative approach to optimizing patient care. Drs. Morgans and Shore also highl...

Real-World Treatment Trends in Metastatic Castration-Sensitive Prostate Cancer - Pedro Barata

Details
Alicia Morgans and Pedro Barata highlight real-world data understanding the metastatic prostate cancer setting, capturing data on patients treated for metastatic hormone-sensitive and then metastatic castration-resistant disease presented at ASCO GU 2022. Clinical trials presented over the past seven years have led to novel hormonal therapies as well as taxane based chemotherapy being approved for...

Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore

Details
Fred Saad, Bertrand Tombal, and Neal Shore join Alicia Morgans in a discussion on the results of the ARASENS trial which examined darolutamide in combination with docetaxel and ADT compared to docetaxel and ADT. They discuss the trial design, its endpoints, how it impacts practice in Canada, the US, and in Europe, and the ideal patient population for this treatment. Biographies: Neal Shore, MD, FA...

ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine publication on the international, phase 3 ARASENS trial. The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 2...

Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi

Details
Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...